ProWomanProLife

  • The Story
  • The Women
  • Notable Columns
  • Contact Us
You are here: Home / All Posts / This one’s for men

This one’s for men

July 16, 2011 by Jennifer Derwey Leave a Comment

Pharmaceutical companies are first and foremost companies. It’s not in their best interest to make one-shot wonder drugs that get you sorted out for life, so they aren’t on the market. Contraceptives are no different. With over 50% of women in the US using “The Pill”, that is big business. Multiply that by their average length of usage, which from the women I’ve spoken to can be anywhere from 5 to 35 years, and you’ve got yourself a money making scheme with serious longevity. So will this new male contraceptive see the light of day?

After a more than 30-year struggle, an unassuming Indian engineer named Sujoy K. Guha is on the brink of what could well be the most revolutionary contraceptive technology since the pill — and this time it’s for men. […]

So what you get is a one-time, hormone-free sperm blocker that you can turn off whenever you want. […]

“We had no support from industry,” Guha said. “And basically neither I nor my colleagues were really knowledgeable and experienced with respect to new drug development.”

Part of the problem was the elegance of Guha’s design, which from a marketing perspective was, frankly, too effective.

“To men, an ideal method would be cheap and long-lasting. To company shareholders, an ideal method would be expensive and temporary,” Lissner explained by email.

“Pharmaceutical companies have no incentive to develop a cheap long-lasting method, and we can’t expect them to take the lead. Men will get one if, and only if, they demand it of their governments,” she said.

I’m not in favour of this drug, but this article exposes the problem with pharmaceutical companies not wanting to make anything “too effective”. What’s worse is that they tie themselves to social issues in a way that has sway on public opinion (throwing a few million to advertising for Marie Stopes is going to have big impact). They simply won’t manufacture a product or support an organization that won’t make them serious bank, social impact be damned. And this is a problem, because the consumer/patient ends up with a product that they’re told is in their best interest when it’s really in the best interest of the company. I’m not sure we can have it both ways.

Facebooktwitterredditpinterestlinkedintumblrmailby feather

Filed Under: All Posts

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebooktwitterrssby feather

Notable Columns

  • A pro-woman budget wouldn't tell me how to live my life
  • Bad medicine
  • Birth control pills have side effects
  • Canada Summer Jobs debacle–Can Trudeau call abortion a right?
  • Celebrate these Jubilee jailbirds
  • China has laws against sex selection. But not Canada. Why?
  • Family love is not a contract
  • Freedom to discuss the “choice”
  • Gender quotas don't help business or women
  • Ghomeshi case a wake-up call
  • Hidden cost of choice
  • Life at the heart of the matter
  • Life issues and the media
  • Need for rational abortion debate
  • New face of the abortion debate
  • People vs. kidneys
  • PET-P press release
  • Pro-life work is making me sick
  • Prolife doesn't mean anti-woman
  • Settle down or "lean in"
  • Sex education is all about values
  • Thank you, Camille Paglia
  • The new face of feminism
  • Today’s law worth discussing
  • When debate is shut down in Canada’s highest places
  • Whither feminism?

Categories

  • All Posts
  • Assisted Suicide/Euthanasia
  • Charitable
  • Ethics
  • Featured Media
  • Featured Posts
  • Feminism
  • Free Expression
  • International
  • Motherhood
  • Other
  • Political
  • Pregnancy Care Centres
  • Reproductive Technologies

All Posts

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Copyright © 2026 · News Pro Theme on Genesis Framework · WordPress · Log in